Tower Research Capital LLC TRC Increases Stock Holdings in Cutera, Inc. (NASDAQ:CUTR)

Tower Research Capital LLC TRC boosted its stake in Cutera, Inc. (NASDAQ:CUTR) by 112.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,363 shares of the medical device company’s stock after acquiring an additional 4,430 shares during the period. Tower Research Capital LLC TRC’s holdings in Cutera were worth $29,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Fox Run Management L.L.C. boosted its stake in shares of Cutera by 43.8% during the 3rd quarter. Fox Run Management L.L.C. now owns 15,130 shares of the medical device company’s stock valued at $91,000 after purchasing an additional 4,607 shares in the last quarter. Gamco Investors INC. ET AL grew its holdings in shares of Cutera by 0.6% during the 3rd quarter. Gamco Investors INC. ET AL now owns 1,144,646 shares of the medical device company’s stock worth $6,891,000 after acquiring an additional 7,040 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Cutera in the 3rd quarter worth approximately $43,000. PNC Financial Services Group Inc. lifted its stake in shares of Cutera by 75.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the medical device company’s stock valued at $132,000 after purchasing an additional 9,472 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Cutera in the 4th quarter valued at approximately $43,000. 90.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Stephens reiterated an “overweight” rating and issued a $10.00 price objective on shares of Cutera in a report on Friday, March 22nd. William Blair upgraded shares of Cutera from an “underperform” rating to a “market perform” rating in a research note on Friday, March 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.75.

Cutera Trading Down 1.6 %

NASDAQ:CUTR traded down $0.04 during trading hours on Friday, reaching $2.53. 475,027 shares of the company traded hands, compared to its average volume of 968,525. The business’s 50-day moving average price is $1.98 and its two-hundred day moving average price is $2.55. Cutera, Inc. has a 1 year low of $1.28 and a 1 year high of $21.47. The stock has a market capitalization of $50.45 million, a P/E ratio of -0.34 and a beta of 1.43.

Cutera (NASDAQ:CUTR) last issued its quarterly earnings results on Thursday, March 21st. The medical device company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($1.07). The firm had revenue of $49.54 million during the quarter, compared to analysts’ expectations of $49.10 million. As a group, equities analysts anticipate that Cutera, Inc. will post -5.88 EPS for the current year.

Cutera Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.